JP7780420B2 - Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物 - Google Patents

Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物

Info

Publication number
JP7780420B2
JP7780420B2 JP2022506062A JP2022506062A JP7780420B2 JP 7780420 B2 JP7780420 B2 JP 7780420B2 JP 2022506062 A JP2022506062 A JP 2022506062A JP 2022506062 A JP2022506062 A JP 2022506062A JP 7780420 B2 JP7780420 B2 JP 7780420B2
Authority
JP
Japan
Prior art keywords
dopa
fasudil
dyskinesia
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542305A5 (https=
JP2022542305A (ja
Inventor
ムニョス・パティーノ，アナ・エム
ラバンデイラ・ガルシア，ホセ・ルイス
ロペス・ロペス，アンドレア
Original Assignee
ウニベルシダーデ デ サンティアゴ デ コンポステーラ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシダーデ デ サンティアゴ デ コンポステーラ filed Critical ウニベルシダーデ デ サンティアゴ デ コンポステーラ
Publication of JP2022542305A publication Critical patent/JP2022542305A/ja
Publication of JP2022542305A5 publication Critical patent/JP2022542305A5/ja
Priority to JP2025141689A priority Critical patent/JP2025169440A/ja
Application granted granted Critical
Publication of JP7780420B2 publication Critical patent/JP7780420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022506062A 2019-07-31 2020-07-24 Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物 Active JP7780420B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141689A JP2025169440A (ja) 2019-07-31 2025-08-27 Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201930713A ES2804076B2 (es) 2019-07-31 2019-07-31 Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa
ESP201930713 2019-07-31
PCT/ES2020/070482 WO2021019116A1 (es) 2019-07-31 2020-07-24 Composición farmacéutica para su uso en el tratamiento profiláctico y/o terapéutico de discinesias inducidas por l-dopa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141689A Division JP2025169440A (ja) 2019-07-31 2025-08-27 Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物

Publications (3)

Publication Number Publication Date
JP2022542305A JP2022542305A (ja) 2022-09-30
JP2022542305A5 JP2022542305A5 (https=) 2024-09-11
JP7780420B2 true JP7780420B2 (ja) 2025-12-04

Family

ID=74229008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506062A Active JP7780420B2 (ja) 2019-07-31 2020-07-24 Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物
JP2025141689A Pending JP2025169440A (ja) 2019-07-31 2025-08-27 Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141689A Pending JP2025169440A (ja) 2019-07-31 2025-08-27 Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物

Country Status (8)

Country Link
US (2) US11337985B2 (https=)
EP (1) EP4005574B1 (https=)
JP (2) JP7780420B2 (https=)
KR (1) KR20220050905A (https=)
CN (1) CN114401725A (https=)
CA (1) CA3145360A1 (https=)
ES (2) ES2804076B2 (https=)
WO (1) WO2021019116A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804076B2 (es) * 2019-07-31 2021-07-12 Univ Santiago Compostela Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804076B2 (es) * 2019-07-31 2021-07-12 Univ Santiago Compostela Composicion farmaceutica para su uso en el tratamiento profilactico y/o terapeutico de discinesias inducidas por l-dopa

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Angelo P. Tanna et al.，Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension，Ophthalmology，2018年，Vol.125, No.11，Pages 1741-1756
Caryl Sortwell et al.，Fasudil administration elevates striatal dopamine and protects against alpha synuclein mediated toxicity，Journal of Parkinson's Disease，2013年，Vol.3, No.Supplement 1，Page 54, Abstract No.P02.11
瀬戸 実 ほか，Rhoキナーゼ阻害薬，日本薬理学雑誌，2011年，Vol.138, No.3，Pages 112-116

Also Published As

Publication number Publication date
JP2025169440A (ja) 2025-11-12
EP4005574C0 (en) 2024-07-03
US20220211719A1 (en) 2022-07-07
US11337985B2 (en) 2022-05-24
ES2804076A1 (es) 2021-02-03
KR20220050905A (ko) 2022-04-25
WO2021019116A1 (es) 2021-02-04
CA3145360A1 (en) 2021-02-04
ES2804076B2 (es) 2021-07-12
JP2022542305A (ja) 2022-09-30
EP4005574A4 (en) 2023-05-24
ES2987334T3 (es) 2024-11-14
US12465613B2 (en) 2025-11-11
EP4005574B1 (en) 2024-07-03
US20210393646A1 (en) 2021-12-23
CN114401725A (zh) 2022-04-26
EP4005574A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
Zhang et al. Mitophagy in neurological disorders
Lu et al. Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation
Gardoni et al. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias
Bordia et al. Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson’s disease
Yuan et al. Treatment strategies for Parkinson’s disease
Maiese Cutting through the complexities of mTOR for the treatment of stroke
Fiorentini et al. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease
US20180177839A1 (en) Modulation of Physiological Processes and Agents Useful for Same
JP2025169440A (ja) Ｌ－ドパ誘発性ジスキネジアの予防的及び／又は治療的処置において使用するための医薬組成物
Zhao et al. Theanine attenuates hippocampus damage of rat cerebral ischemia-reperfusion injury by inhibiting HO-1 expression and activating ERK1/2 pathway
Pagano et al. PET molecular imaging research of levodopa-induced dyskinesias in Parkinson’s disease
Sasaki et al. Evaluation of canthinone alkaloids as cerebral protective agents
US11246871B2 (en) Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
Zhong et al. HC067047 ameliorates sepsis-associated encephalopathy by suppressing endoplasmic reticulum stress and oxidative stress-induced pyroptosis in the hippocampi of mice
Wang et al. Acetyl‐L‐carnitine improves erectile function in bilateral cavernous nerve injury rats via promoting cavernous nerve regeneration
Yao et al. Tryptophan metabolism and ischemic stroke: An intricate balance
US20040127571A1 (en) Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate
Sawant et al. An update on novel and emerging therapeutic targets in Parkinson’s disease
WO2011047412A1 (en) Tyrosine and l-dopa for reducing l-dopa incorporation into proteins
Smith et al. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates
CA3142899A1 (en) Treatment for synucleinopathies
Gamir-Morralla et al. A novel neuroprotection target with distinct regulation in stroke and Alzheimer’s disease
JP2023513403A (ja) パーキンソン病の治療における使用のための、アネトールトリチオンまたはその誘導体４－ｏｈ－アネトールトリチオンとドキシサイクリンまたはミノサイクリンとの組合せ
Spinnewyn et al. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson’s disease
Dincer Pharmacoepigenetics of Memantine in Dementia

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251121

R150 Certificate of patent or registration of utility model

Ref document number: 7780420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150